Heim524816 • BOM
add
Natco Pharma Ltd.
Við síðustu lokun
1.389,35 ₹
Dagbil
1.364,80 ₹ - 1.403,00 ₹
Árabil
725,00 ₹ - 1.638,35 ₹
Markaðsvirði
250,57 ma. INR
Meðalmagn
53,76 þ.
V/H-hlutf.
15,33
A/V-hlutfall
0,39%
Aðalkauphöll
NSE
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
(INR) | jún. 2024info | Breyting á/á |
---|---|---|
Tekjur | 13,63 ma. | 19,47% |
Rekstrarkostnaður | 4,22 ma. | 3,11% |
Nettótekjur | 6,68 ma. | 59,05% |
Hagnaðarhlutfall | 49,06 | 33,13% |
Hagnaður á hvern hlut | 37,32 | 60,45% |
EBITDA | 8,07 ma. | 40,06% |
Virkt skatthlutfall | 16,81% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
(INR) | jún. 2024info | Breyting á/á |
---|---|---|
Reiðufé og skammtímafjárfestingar | 18,49 ma. | 59,13% |
Heildareignir | — | — |
Heildarskuldir | — | — |
Eigið fé alls | 58,53 ma. | — |
Útistandandi hlutabréf | 179,13 m. | — |
Eiginfjárgengi | 4,25 | — |
Arðsemi eigna | — | — |
Ávöxtun eigin fjár | 30,55% | — |
Peningaflæði
Breyting á handbæru fé
(INR) | jún. 2024info | Breyting á/á |
---|---|---|
Nettótekjur | 6,68 ma. | 59,05% |
Handbært fé frá rekstri | — | — |
Reiðufé frá fjárfestingum | — | — |
Reiðufé frá fjármögnun | — | — |
Breyting á handbæru fé | — | — |
Frjálst peningaflæði | — | — |
Um
Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad with a presence in formulation and active pharmaceutical ingredients in both domestic and international markets. The company also manufactures Agro chemical products. It is a major producer of branded oncology medicines cardiology, diabetology and other pharma specialty drugs. The company specialises in producing complex medicines at affordable prices. The company has a presence in 50+ countries. NATCO is a science driven company and focuses on limited competition molecules in the US .The company’s pharma division has 5 manufacturing facilities, 2 API and intermediate manufacturing facilities and the crop health sciences division has one formulation and one technical manufacturing facility. The company boasts of having a talent pool of 450+ scientists working out of two research centers in India.
Across the globe, cancer treatment saw a sea change in early 2000s in terms of screening, diagnosis, molecular pathology, targeted therapies, immunotherapies, Bone Marrow Transplants, and supportive care. Wikipedia
Framkvæmdastjóri
Stofnsett
1981
Höfuðstöðvar
Vefsvæði
Starfsfólk
4.016